Blood tumor mutational burden (bTMB) and tumor PD-L1 as predictive biomarkers of survival in MYSTIC: First-line durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in metastatic (m) NSCLC.

Naiyer A. Rizvi,Byoung Chul Cho,Niels Reinmuth,Ki Hyeong Lee,Alexander Luft,Myung-Ju Ahn,Michel van den Heuvel,Manuel Cobo Dols,David Vicente,Alexey Smolin,Vladimir Moiseyenko,Scott Joseph Antonia,Kazuhiko Nakagawa,Sarah B. Goldberg,Edward S. Kim,Jill Walker,Rajiv Raja,Feng Liu,Urban J. Scheuring,Solange Peters

DOI: https://doi.org/10.1200/JCO.2019.37.15_suppl.9016

IF: 45.3

2019-10-07

Journal of Clinical Oncology

Abstract:9016 Background: MYSTIC, an open-label, Ph3 trial of first-line D (anti-PD-L1) ± T (anti-CTLA-4) vs platinum-based CT, showed an improvement in OS with D vs CT in pts with tumor cell PD-L1 expression ≥25% (PD-L1 TC ≥25%; HR 0.76 [97.54% CI 0.56–1.02], p = 0.036). Exploratory analyses showed bTMB was a predictive biomarker for OS with D±T vs CT. We report further exploratory analyses of OS according to PD-L1 and bTMB. Methods: Immunotherapy/CT-naïve pts with mNSCLC were randomized (1:1:1) to D, D+T or CT. bTMB levels (mut/Mb) were evaluated with the GuardantOMNI platform (Guardant Health), and PD-L1 TC expression with the VENTANA PD-L1 (SP263) IHC assay. Results: D improved OS vs CT in pts with PD-L1 TC ≥25% across bTMB levels (PD-L1 TC ≥25%/bTMB≥20 HR 0.79 [95% CI 0.45, 1.39]; PD-L1 TC ≥25%/bTMB < 20 HR 0.64 [95% CI 0.45, 0.90]). In contrast, D+T improved OS vs CT in pts with bTMB≥20 across different PD-L1 TC expression levels (Table; PD-L1 TC ≥25%/bTMB≥20 HR 0.44 [95% CI 0.23, 0.84]; PD-L1 TC < 1%/bTMB≥20 HR 0.42 [95% CI 0.17, 0.97]). Additional cutoffs and outcomes in subgroups defined by both biomarkers will be presented. Conclusions: These exploratory analyses from MYSTIC support PD-L1 TC expression as an appropriate predictive biomarker for OS with D vs CT, while suggesting bTMB as a predictive biomarker for OS with D+T in mNSCLC. These biomarkers appear to be independent and both may be important for mNSCLC treatment decisions. Interpretation of these data may be limited by small sample sizes; further investigations are warranted. Clinical trial information: NCT02453282. D D+T PD-L1 TC ≥25% PD-L1 TC ≥1% PD-L1 TC < 1% PD-L1 TC ≥25% PD-L1 TC ≥1% PD-L1 TC < 1% All pts, n N = 163 N = 279 N = 95 N = 163 N = 296 N = 76 HR* (95% CI) 0.76 (0.56, 1.02)† 0.88 (0.73, 1.07) 1.18 (0.86, 1.62) 0.85 (0.61, 1.17)‡ 1.01 (0.83, 1.21) 0.73 (0.51, 1.04) bTMB ≥20, n N = 40 N = 61 N = 16 N = 32 N = 49 N = 15 HR* (95% CI) 0.79 (0.45, 1.39) 0.74 (0.48, 1.13) 0.68 (0.32, 1.42) 0.44 (0.23, 0.84) 0.52 (0.32, 0.83) 0.42 (0.17, 0.97) bTMB < 20, n N = 91 N = 152 N = 57 N = 81 N = 164 N = 40 HR* (95% CI) 0.64 (0.45, 0.90) 0.79 (0.61, 1.03) 1.38 (0.89, 2.18) 1.16 (0.83, 1.63) 1.21 (0.95, 1.55) 0.99 (0.60, 1.62) *HRs refer to comparison of immunotherapy to CT; †97.54% CI; ‡98.77% CI

oncology